Stock Analysis

Newron Pharmaceuticals Full Year 2022 Earnings: €0.98 loss per share (vs €0.83 loss in FY 2021)

Source: Shutterstock

Newron Pharmaceuticals (VTX:NWRN) Full Year 2022 Results

Key Financial Results

  • Revenue: €6.09m (up 5.8% from FY 2021).
  • Net loss: €17.5m (loss widened by 17% from FY 2021).
  • €0.98 loss per share (further deteriorated from €0.83 loss in FY 2021).
SWX:NWRN Earnings and Revenue History March 17th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Newron Pharmaceuticals Earnings Insights

Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Switzerland.

The company's shares are down 6.0% from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Newron Pharmaceuticals that you should be aware of before investing here.

Valuation is complex, but we're helping make it simple.

Find out whether Newron Pharmaceuticals is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis